- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor https://www.cell.com/cell/fulltext/s0092-8674(20)30229-4?rss=yes#%20 4 comments worldnews
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor https://www.cell.com/cell/fulltext/s0092-8674(20)30229-4?rss=yes 4 comments science
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor https://www.cell.com/cell/pdf/s0092-8674(20)30229-4.pdf 137 comments science
- In Vitro Cellular Work Shows SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor https://www.cell.com/cell/fulltext/s0092-8674(20)30229-4?rss=yes 5 comments science
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor: Camostat mesylate, an inhibitor of TMPRSS2, blocks SARS-CoV-2 infection of lung cells. https://www.cell.com/action/showpdf?pii=s0092-8674%2820%2930229-4 101 comments science